Recent Press Releases

Pandion Therapeutics Launches Type 1 Diabetes Focused Program with Investment from JDRF T1D Fund

CAMBRIDGE AND BOSTON, MA – December 19, 2018 – Pandion Therapeutics, a biotechnology platform company developing therapeutics to achieve localized immunomodulation to treat autoimmune and inflammatory disease, today announced it has received an investment from the JDRF T1D Fund. This financing will enable the company to launch a type 1 diabetes (T1D)-focused program leveraging its innovative technology platform...


ImmusanT Expands Platform to Type 1 Diabetes with Investment from JDRF T1D Fund

CAMBRIDGE, Mass. – September 11, 2018 – ImmusanT, Inc., a clinical stage company that is leveraging its Epitope-Specific Immuno-Therapy™ (ESIT™) platform to translate and deliver first-in-class peptide-based immune therapies to people living with autoimmune diseases, today announced that it has received an investment from the JDRF T1D Fund, a venture philanthropy fund...


Inversago Pharma receives $7 million in series A financing

MONTREAL (CANADA) – July 25, 2018 – Proceeds will support the development of novel generation cannabinoid receptor type 1 (CB1) inverse agonists for the treatment of several metabolic diseases including Prader-Willi Syndrome (PWS) and type 1 diabetes (T1D). Today Inversago Pharma Inc. (“Inversago”) announced that it has secured a $7 million series A financing to pursue...


Enthera, the first spin-off of BiovelocITA, completed €4 million seed-expansion financing

Milan – July 24, 2018 – Enthera S.r.l. is an innovative start-up founded in 2016 by Prof. PaoloFiorina, Dr. Francesca D’Addio and by BiovelocITA. Enthera is dedicated to the research and developmentof innovative approaches to treat type 1 diabetes and related gastrointestinal complications. The seedexpansion, led by Sofinnova Partners, a leading European...


JDRF T1D Fund Expands Investment Team with Appointment of Katie Ellias as Managing Director

BOSTON – July 18, 2018 – The JDRF T1D Fund, a venture philanthropy fund focused on accelerating life-changing solutions to treat, prevent, and cure type 1 diabetes (T1D) through catalytic commercial investments, today announced that Katie Ellias has joined the fund as its second Managing Director. The JDRF T1D Fund, a venture philanthropy fund focused...